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Background: Chronic myeloid leukemia is caused by a chro-
mosomal translocation that results in an oncogenic fusion
protein, Bcr-Abl. Bcr-Abl is a tyrosine kinase whose activity
is inhibited by the antineoplastic drug STI571. This drug can
cure mice given an injection of human leukemic cells, but
treatment ultimately fails in animals that have large tumors
when treatment is initiated. We created a mouse model to
explore the mechanism of resistance in vivo. Methods: Nude
mice were injected with KU812 Bcr-Abl+ human leukemic
cells. After 1 day (no evident tumors), 8 days, or 15 days
(tumors >1 g), mice were treated with STI571 (160 mg/kg
every 8 hours). Cells recovered from relapsing animals were
used for in vitro experiments. Statistical tests were two-sided.
Results: Tumors regressed initially in all STI571-treated
mice, but all mice treated 15 days after injection of tumor
cells eventually relapsed. Relapsed animals did not respond
to further STI571 treatment, and their Bcr-Abl kinase ac-
tivity in vivo was not inhibited by STI571, despite high
plasma concentrations of the drug. However, tumor cells
from resistant animals were sensitive to STI571 in vitro, sug-
gesting that a molecule in the plasma of relapsed animals
may inactivate the drug. The plasma protein 1 acid glyco-
protein (AGP) bound STI571 at physiologic concentrations
in vitro and blocked the ability of STI571 to inhibit Bcr-Abl
kinase activity in a dose-dependent manner. Plasma AGP
concentrations were strongly associated with tumor load.
Erythromycin competed with STI571 for AGP binding.
When animals bearing large tumors were treated with
STI571 alone or with a combination of STI571 and erythro-
mycin, greater tumor reductions and better long-term tu-
mor-free survival (10 of 12 versus one of 13 at day 180;
P<.001) were observed after the combination treatment.
Conclusion: AGP in the plasma of relapsed animals binds
to STI571, preventing this compound from inhibiting the
Bcr/Abl tyrosine kinase. Molecules such as erythromycin
that compete with STI571 for binding to AGP may enhance
the therapeutic potential of this drug. [J Natl Cancer Inst
2000;92:1641–50]
BCR-ABL, a human oncogenic fusion gene, encodes the hy-
brid Bcr-Abl protein. Through its enhanced, constitutive tyro-
sine kinase activity, BCR-ABL causes chronic myeloid leu-
kemia (CML) and some cases of acute lymphoblastic leukemia
and acute myeloid leukemia (1–3). Inhibition of Bcr-Abl ki-
nase activity is an innovative and rational strategy for treating
CML and other neoplasias caused by this oncogenic fusion pro-
tein (4).
STI571 (formerly known as CGP57148B) is an active and
relatively specific inhibitor of Bcr-Abl kinase activity (5) that
blocks cell proliferation and induces apoptotic cell death in
BCR-ABL+ cells in vitro (6), inhibits the growth of clonogenic
bone marrow cells from CML patients (4,7), and can eradicate
leukemic cell growth in vivo (8). The in vivo activity of STI571
depends on the stable and continuous inhibition of Bcr-Abl;
thus, multiple daily administrations are required in the murine
model studied (8). Currently, STI571 is being tested in initial
clinical trials of patients with CML and other BCR-ABL-
associated diseases.
In our earlier studies (8), treatment with STI571 failed in
some animals when it was started 1 week after leukemic cells
were injected and a measurable mass was present. Limited in-
formation, however, is available on the mechanism of STI571
resistance. Two cell lines have been selected in vitro for resis-
tance to STI571 (9). The mechanism of resistance involves am-
plification of the BCR-ABL gene and protein overexpression in
one line (10) but is unknown in the other line. However, the
biologic relevance of these in vitro-selected sublines remains to
be established because the selection conditions in vitro do not
necessarily reproduce the in vivo situation.
To our knowledge, no in vivo experimental model of resis-
tance to STI571 has been developed and characterized. In this
article, we describe the molecular characterization of a murine
model for in vivo resistance to STI571.
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MATERIALS AND METHODS
STI571
STI571 was provided by Novartis Pharma AG, Basel, Switzerland. It is a
derivative of 2-phenylaminopyrimidine, with a molecular weight of 590. For in
vitro experiments, stock solutions of STI571 were prepared at 1 and 10 mM in
distilled water, filtered, and stored at −20 °C. Preparations used for animal
experiments were made daily at 16 mg/mL in water or 5% methylcellulose
(Methocel MC high viscosity; Sigma–Aldrich Chemie, Steinheim, Germany),
and the solution was kept at 4 °C.
Erythromycin
For in vitro experiments, we used an erythromycin base (Sigma Chemical Co.,
St. Louis, MO). Erythromycin was dissolved in ethanol and then diluted 1 : 1000
in distilled water. For in vivo experiments, we dissolved erythromycin estolate
(provided by DSM Antiinfectives, Capua, Italy) at 35 mg/mL in a solution
containing 5% methylcellulose and 16 mg/mL STI571. The estolate formulation
of erythromycin was chosen because it has good bioavailability when given
orally to mice (11).
In Vivo Administration of STI571
Seven- to 9-week-old female CD1 nu/nu mice purchased from Charles River
Breeding Laboratories (Calco, Italy) were kept under standard laboratory con-
ditions according to the guidelines of the National Cancer Institute, Milan, Italy.
This study was approved by the institutional ethics committee for laboratory
animals used in experimental research of the National Cancer Institute. Approxi-
mately 50 × 106 BCR-ABL+ KU812 cells were injected subcutaneously in the
left flank of each animal. STI571 (at 160 mg/kg every 8 hours for 11–21 con-
secutive days) was administered orally through a syringe connected to a soft
plastic tube introduced into the esophagus (gavage). In all experiments evaluat-
ing the antitumor activity of STI571 in vivo, 12–15 animals were used per group.
Tumor weight (TW) and total weight were monitored every 3 or 4 days. TW was
calculated by the formula TW (mg) (d2 × D/2), where d and D are the shortest
and longest diameters of the tumor, respectively, measured in millimeters. Treat-
ment was started 1, 8, or 15 days after leukemia cells were injected; the three
groups of animals were designated as groups I, II, and III, respectively.
Cell Lines
The BCR-ABL+ human leukemia cell line KU812 was used (12). It was
obtained from a CML patient in blast crisis and was maintained in RPMI-1640
medium (BioWhittaker, Walkersville, MD) supplemented with 5% fetal calf
serum (BioWhittaker).
Determination of the In Vitro Cell Proliferation Activity
([3H]Thymidine Uptake Assay)
Six to eight replicate cultures (200 L), each containing 104 KU812 cells,
were incubated with 0–10 M STI571 in 96-well microtiter plates (Corning
Costar Corp., Cambridge, MA) for 54 hours at 37 °C. After this period, 20 L
of RPMI-1640 medium and 10% fetal calf serum containing [3H]thymidine at a
dose of 1 Ci per well (Du Pont NEN, Boston, MA) were added to each well.
After an additional 18 hours, cells were harvested and transferred to a filter
(Spot-on Filtermat; Pharmacia Biotech Europe, Brussels, Belgium). [3H]Thymi-
dine uptake was measured in a 1205 betaPlate liquid scintillation counter (Wal-
lac Inc., Turku, Finland). The IC50 inhibitory concentration (defined as the
concentration of a compound producing a 50% decrease in proliferation com-
pared with untreated controls) was calculated. In some experiments, human 1
acid glycoprotein (AGP) (Sigma–Aldrich Chemie) or human albumin (Centeon
Pharma, Marburg, Germany) was added to the wells.
Western Blot Analysis
Immunoblotting was performed as described previously (6). Cells were
washed twice with ice-cold phosphate-buffered saline (PBS) and subsequently
lysed in 200 L of 1× Laemmli’s buffer (8) (i.e., 50 mM Tris–HCl [pH 6.8], 2%
sodium dodecyl sulfate, 0.1% bromophenol blue, 10% glycerol, and 5% 2-mer-
captoethanol) Cell lysates (from 90 000–150 000 cells) were heated to 95 °C for
10 minutes and then sonicated for 1 minute. For tumor extracts, tissue was
extracted and homogenized in a fivefold volume of Laemmli’s buffer. After
sonication for 2 minutes, the samples were centrifuged at 15000g for 15 minutes,
heated at 95 °C for 10 minutes, and stored at −80 °C. Proteins in the cell lysates
and tumor extracts were separated by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis on 7.5% gels and transferred to protran nitrocellulose trans-
fere membrane (Schelecher & Schuell, Dassel, Germany). Endogenous Bcr-Abl,
tyrosine-phosphorylated Bcr-Abl, and actin were detected with the correspond-
ing mouse monoclonal antibodies or rabbit antiserum and visualized by en-
hanced chemiluminescence detection (Amersham Corp., Little Chalfont, U.K.)
by use of horseradish peroxidase-linked goat anti-mouse or anti-rabbit immu-
noglobulin G as the secondary antibody (Amersham Corp.). Anti-abl monoclonal
antibody (clone Ab-3) was purchased from Calbiochem Corp. (La Jolla, CA).
Antiphosphotyrosine monoclonal antibody (clone 4G10) was purchased from
Upstate Biotechnology (Lake Placid, NY). Rabbit anti-actin polyclonal antibody
was purchased from Sigma Chemical Co.
Densitometric analysis of western blots was performed with an Eagle Eye II
photodensitometer (Stratagene Cloning Systems, La Jolla, CA), and the inten-
sities of tyrosine-phosphorylated BCR-ABL bands were normalized against the
BCR-ABL expression levels.
AGP Determination
Levels of the inducible plasma protein AGP in serum were evaluated by
immunodiffusion or by isoelectric focusing. For radial immunodiffusion to mea-
sure AGP in mouse serum, we used the single radial immunodiffusion plate test
and antiserum specific for murine or human AGP (Cardiotech Services, Inc.,
Louisville, KY). Five microliters of serum was placed in a well and incubated for
24 hours at 37 °C. The amount of AGP was determined from the diameter of the
precipitin ring by use of AGP standards of 1000, 250, and 125 g/mL that were
provided with the test kit. Determinations were performed in duplicate.
For isoelectric focusing, an immobilized pH gradient (13) from pH 2.5 to pH
5 was cast between an acid solution (i.e., 3 mM Immobiline™ of pK 1 [negative
logarithm of the dissociation constant] 1, 11.83 mM Immobiline of pK 3.6, 0.76
mM Immobiline of pK 9.3, and 12.9 mM Tris) and a basic solution (9.28 mM
Immobiline of pK 3.6, 9.50 mM Immobiline of pK 4.6, and 16.13 mM Immo-
biline of pK 9.3) (Pharmacia, Uppsala, Sweden). After polymerization, the gel
was washed three times with 1% glycerol, dried, and rehydrated in a solution of
8 M urea and 0.5% carrier ampholytes from pH 2.5 to pH 5 (Pharmacia).
Subsequently, 7.5 L of serum, diluted to 25 L with 2% 2-mercaptoethanol,
was loaded near the cathode, and the sample was subjected to electrophoresis
overnight at 55 V/cm and then to isoelectric focusing for 90 minutes at 165
V/cm. The gel was then stained with Coomassie blue.
Estimation of Binding Parameters
Plasma or purified human AGP (Sigma Chemical Co.) or albumin (diluted in
PBS) was incubated at room temperature for 30 minutes with various concen-
trations of STI571, and the concentration of STI571 was determined by high-
pressure liquid chromatography. This procedure has a lower limit of detection of
0.1 M STI571. Free STI571 was determined by ultrafiltration with Centriplus
filters (30-kd cutoff, Amicon; Millipore Corp., Bedford, MA). From these data,
modified Scatchard plots were constructed, and the association constant of
STI571 with each plasma protein was calculated as reported previously (14).
Statistical Analysis
Statistical analysis was performed with two-sided Fisher’s exact test in Fig. 8,
B, and Student’s t test in all of the other experiments by use of the GraphPad
software analysis program (Prism, San Diego, CA). For survival analysis, data
were compared with the log-rank test. P values of less than .05 were considered
to be statistically significant and were derived from two-sided statistical tests.
All data are presented as the mean (95% confidence interval [CI]). CIs are
displayed when they exceed 5% of the respective mean.
RESULTS
STI571 Efficacy and the Initial Tumor Load
Nude mice were injected subcutaneously with 50 × 106
KU812 cells. For treatment, STI571 at 160 mg/kg was admin-
istered every 8 hours for 11 consecutive days, beginning 1, 8, or
15 days after tumor cells were injected (groups I–III, respec-
tively) when 50 million, 300 million, or 1 billion leukemic cells
were present in a tumor. Tumor growth in control animals (i.e.,
1642 ARTICLES Journal of the National Cancer Institute, Vol. 92, No. 20, October 18, 2000
given an injection of tumor cells but treated with water only) was
detected between days 5 and 12 (data not shown). Tumor re-
gression was initially observed in all groups. However, although
all animals in group I were cured (by 80 days or longer), 33% of
the mice in group II relapsed between days 24 and 34 (range,
33%–40%; n  3 experiments) (Fig. 1, A). No cure was ob-
served in group III (data not shown). Relapses usually developed
1–3 weeks after treatment was discontinued. When data from
groups I, II, and III were compared (Fig. 1, B), a clear relation-
ship was observed between the amount of tumor present at the
beginning of treatment and the outcome of the therapy. To de-
termine whether the period of treatment with STI571 was long
enough in groups II and III, we treated two groups of mice in
group II with STI571 for either 11 or 18 days. However, we
observed the same percentage (40%) of relapses in both groups
(data not shown), indicating that a longer period of treatment did
not substantially improve the rate of cure. These results indicate
that, in this model, treatment with STI571 can cure animals
bearing 8-day-old tumors only if the neoplasia is eradicated in
the first 11 days of treatment; if this does not happen, cure
cannot be achieved, even with longer exposure to STI571.
Relapsed Tumors With In Vivo STI571 Resistance but In
Vitro STI571 Sensitivity
Animals with recurrent tumors were treated a second time
with STI571 on the same 11-day schedule. Treatment was
started as soon as tumors were measurable. Recurrent tumors
responded poorly to the treatment and eventually started to grow
at a rate resembling that of tumors in untreated animals (Fig. 2).
Only one of five tumors (from the animal with the smallest
initial tumor) failed to regrow during the second round of treat-
ment. To determine the intrinsic in vitro sensitivity of the recur-
rent tumor cells to STI571, we excised tumors from STI571-
resistant animals and dissociated, cultured, and tested the cells
for their sensitivity to STI571 within 48 hours, as described
previously (6) (Fig. 3).
Tumor cells from STI571-resistant animals were found to still
be sensitive to STI571. The STI571 IC50 values of these cells
and the parental KU812 cell line were similar. These results
prompted us to determine whether the Bcr-Abl kinase activity in
the tumors of STI571-resistant mice was still inhibited by
STI571 by performing molecular pharmacokinetics experiments
Fig. 1. Initial tumor load and the ability of
STI571 to cure tumor-bearing animals. Panel A:
Nude mice were given an injection of 50 × 106
BCR-ABL+ KU812 leukemic cells on day 1.
Treatment with STI571 (160 mg/kg orally every
8 hours for 11 days) was started on day 2 (solid
squares  no measurable tumor present) or on
day 9 (solid diamondsmean tumor weight
276 mg; 95% confidence interval [CI]  179–
373). The percentage of animals with tumor-free
survival is presented as a function of time after
tumor cell injection. Numbers in parentheses
indicate the number of animals at risk. The P
value is from a two-sided test. Panel B: Nude
mice given an injection of KU812 cells were
treated with STI571 (same schedule as in panel
A) on day 2 (group I), on day 9 (group II: mean
tumor weight  253 mg; 95% CI  131–375),
or on day 16 (group III; mean tumor weight 
1054 mg; 95% CI 796–1312). The percentage
of animals cured is presented for each group.
The results represent the mean of three consecu-
tive experiments with 95% CIs. CIs are dis-
played only when they exceed 5% of the respec-
tive mean.
Journal of the National Cancer Institute, Vol. 92, No. 20, October 18, 2000 ARTICLES 1643
(8). In these experiments, we investigated the degree and dura-
tion of Bcr-Abl inhibition in tumor-bearing animals that either
were sensitive or were resistant to STI571. Mice in both groups
were treated acutely with STI571 (160 mg/kg orally) and killed
2, 4, or 6 hours later. The levels of Bcr-Abl kinase activity
(measured as autophosphorylation) are shown in Fig. 4. Al-
though tumor extracts from STI571-sensitive mice showed
the previously reported inhibition (8) of Bcr-Abl phosphoryla-
tion at 2 and 4 hours (Fig. 4, lanes 4 and 6; 80% and 50%
inhibition by densitometric analysis, respectively), Bcr-Abl
phosphorylation in STI571-resistant animals was not inhibited
by the STI571 treatment (lanes 3 and 5). Thus, in STI571-
resistant mice, Bcr-Abl kinase activity was not inhibited by
STI571 treatment in vivo, even though tumor cells isolated from
these animals were sensitive to STI571.
Consequently, we investigated whether animals treated with
STI571 compensated by increasing their metabolism of STI571,
thereby decreasing the concentration of STI571 in plasma to a
level that would not inhibit Bcr-Abl activity. Tumor-bearing
mice (three or four animals per group, one that was sensitive to
STI571 and one that was resistant to STI571) were killed at 30
minutes, 2 hours, and 5 hours after an acute treatment with
STI571 (160 mg/kg). Total concentrations of STI571 in the
plasma and the tumor were determined by reverse-phase high-
pressure liquid chromatography. This method can detect 0.1 M
STI571 (lower limit). STI571-sensitive (i.e., control) animals
and STI571-resistant animals reached statistically nonsignifi-
cantly different levels of STI571 in plasma at 30 minutes (13.9
M [95% CI  2.5–25.3] versus 8.51 M [95% CI  1.3–
15.7]; P  .35). These levels were substantially higher than
those required to inhibit the activity of Bcr-Abl (0.1–1 M) (6).
At 2 hours (5.8 M [95% CI 2.8–8.8] versus 8.4 M [95% CI
Fig. 2. Appearance of STI571-resistant
tumors in animals that had an initial
positive response to STI571. Weights
of tumors in five animals are shown.
Tumors first responded to an STI571
treatment of 160 mg/kg orally every 8
hours for 18 days. If the tumor re-
curred, animals were treated with
STI571 as soon as the tumor was mea-
surable. Weights of the tumor at vari-
ous times after the initiation of treat-
ment are shown. Dashed lines show
the growth of two untreated tumors.
Different symbols indicate individual
animals.
Fig. 3. In vitro sensitivity to STI571 of two in vivo STI571-resistant
tumors. Tumors from two animals that were resistant to a second course
of treatment with STI571 were excised 72 hours after treatment was
discontinued. Tumor cells were isolated and placed in culture; 48 hours
later, their in vitro sensitivity to STI571 was assessed by measuring cell
proliferation with a [3H]thymidine uptake assay (6). Parental KU812
cells were included for comparison. Values are expressed as the percent
of untreated control cells. The results represent the mean of three
consecutive experiments with 95% confidence intervals (CIs). CIs are
displayed when they exceed 5% of the respective mean.
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 1.4–15.4]; P  .36) and 5 hours (2.1 M [95% CI  1.3–
2.9] versus 5.7 M [95% CI  4.5–6.9]; P<.001), an even
greater decrease was observed in STI571 levels in STI571-
sensitive animals as compared with STI571-resistant animals.
There was a tendency toward lower STI571 concentrations in
tumors of STI571-resistant animals (data not shown). These pre-
liminary results did not support our initial hypothesis that ani-
mals treated with STI571 compensate by increasing the metabo-
lism of this compound. These data were instead compatible with
the presence of a factor in the blood of STI571-resistant mice
that binds to and thus decreases the biologic activity of STI571.
AGP Binding of STI571
Two plasma proteins that can bind drugs are albumin and
AGP (14), and AGP preferentially binds basic molecules;
STI571, in fact, contains several residues that can confirm a
basic potential to this. BCR-ABL+ KU812 cells were used to
assess the ability of AGP to alter the STI571-mediated inhibition
of cell proliferation. Because murine AGP was not available in
quantities sufficient for this experiment (15), human AGP was
used. AGP inhibited the effect of STI571 (measured as IC50) in
a concentration-dependent manner (Fig. 5, A). The IC50 value
for STI571 increased from 0.05 M in the absence of AGP to
greater than 3.0 M in the presence of AGP at 2 mg/mL. In a
separate experiment, the IC50 value for STI571 in the presence
of AGP at 2 mg/mL was calculated to be 4.5 M, an increase of
90-fold (data not shown). By contrast, albumin did not substan-
tially increase the IC50 for STI571, even at 35 mg/mL (Fig. 5, B).
The association constants for the binding of STI571 to AGP
and to albumin were then calculated. We incubated 5 M AGP
with various STI571 concentrations and determined the amount
of unbound drug (i.e., the free fraction) by ultrafiltration.
Scatchard analyses were done for AGP and albumin to deter-
Fig. 4. In vivo STI571-mediated inhibition of BCR-ABL autophosphorylation.
Tumor-bearing mice were acutely treated with STI571 (160 mg/kg orally) and
killed 2, 4, or 6 hours later. Tumor extracts were made and used for western blot
analysis with antiphosphotyrosine (ptyr) to detect phosphorylated Bcr-Abl or
anti-Abelson (abl) to detect total Bcr-Abl. Ctrl tumor extract from animals not
pretreated with STI571; Rel  tumor extract from animals pretreated with
STI571 that relapsed and were resistant to further STI571 treatment; and n.t.
not treated. Similar data were obtained from three other animals.
Fig. 5. Effect of 1 acid glycoprotein (AGP) (panel
A) and albumin (panel B) on the in vitro sensitivity of
KU812 cells to STI571. KU812 cells were cultured
with AGP (0–2 mg/mL), with albumin (0–35 mg/mL),
or with neither, and the sensitivity to STI571 was as-
sessed after 48 hours as described previously (6) by
[3H] thymidine uptake assay. Data from one represen-
tative experiment are shown. The experiment was per-
formed three times with similar results. The results
represent one representative experiment with 95%
confidence intervals (CIs). CIs are displayed when
they exceed 5% of the respective mean.
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mine the association constants of STI571 to this protein. The
association constant for AGP was 4.9 × 106 L/mol, which is
approximately 21 times higher than the association constant cal-
culated for albumin (2.3 × 105 L/mol). These results indicate
that, although albumin and AGP can bind STI571, the latter
binds STI571 with a much higher affinity and thus lowers the
concentration of active STI571 more effectively.
We confirmed these results in a [3H]thymidine uptake assay
with KU812 cells with the use of sera containing different
amounts of AGP. KU812 cells were incubated with serum con-
taining either 330 (serum A) or 1150 (serum B) g of AGP per
mL that was added to the culture medium at a final concentration
of 25% (vol/vol) for 72 hours. The calculated IC50 values for
STI571 were 0.1 M without added serum, 0.4 M with serum
A, and greater than 2 M with serum B. Although these results
do not exclude other serum factors, the IC50 value for STI571
appears to increase in an AGP concentration-dependent manner.
Thus, AGP can bind STI571, and this binding blocks the ability
of STI571 to inhibit the proliferative activity of BCR-ABL+ cells
and, consequently, has important biologic consequences.
Relationship of AGP Serum Levels, Tumor Load, and
STI571 Treatment
Because AGP potently interfered with the ability of STI571
to inhibit the proliferation of BCR-ABL+ cells in vitro, we mea-
sured the levels of AGP in the plasma of nude mice 8 and 15
days after the injection of KU812 cells. We used these data to
determine whether there was an association between the in vivo
sensitivity of KU812 cells to STI571 and the level of AGP in the
corresponding mouse plasma. As measured by immunodiffu-
sion, basal levels of AGP in control mice that had not received
an injection of tumor cells were very low (96 g/mL [95% CI
75–117]; Fig. 6, A). In tumor-bearing mice, the AGP concen-
tration increased proportionally with the tumor load. Mice with
a tumor load of 200–300 mg (8 days after tumor cell injection)
showed a fourfold increase in AGP (383 g/mL; 95% CI 
252–514), and mice with a tumor load of 0.8–1 g (15–20 days
after tumor cell injection) had a mean AGP level of 1580 g/mL
(95% CI  1346–1814). Animals with measurable tumors
showed a progressive decrease in plasma AGP levels as the
tumors were cured; these AGP levels returned to normal in cured
animals 4–8 weeks after the start of the treatment. The amount
of AGP observed in the plasma of normal mice corresponded to
an in vitro AGP-bound STI571 fraction of 42% at an STI571
concentration of 7 M, and the amount observed in the plasma
of mice bearing large tumors corresponded to an AGP-bound
STI571 fraction of more than 99% (data not shown). After treat-
ment of control mice with STI571 at 160 mg/kg orally for 11
days, treated mice had a lower, but statistically significant, in-
crease in the amount of plasma AGP (213 g/mL; 95% CI 
170–256) compared with non-STI571-treated mice. Increased
AGP levels in tumor-bearing mice were also detected by iso-
electrofocusing (Fig. 6, B). Thus, tumor load (and, to a lesser
extent, STI571 pretreatment) induced the synthesis of AGP, a
plasma protein that, in turn, could bind and effectively inactivate
STI571.
Erythromycin and Its Competition With STI571 for
AGP Binding
Several drugs, including erythromycin (15), can bind to AGP.
If the binding of STI571 to AGP effectively inhibits the ability
of STI571 to block cell division and inhibit Bcr-Abl kinase
activity, then a molecule that binds to the same site on AGP
could compete with STI571 and thus increase the concentration
of free STI571. To test this possibility, we added 5–30 M
erythromycin to KU812 cultures containing STI571 and/or AGP
and assessed cell proliferation (Fig. 7, A). In the presence of
AGP, erythromycin restored the sensitivity of KU812 cells to
Fig. 6. Determination of 1 acid glycoprotein (AGP) in normal and tumor-
bearing mice by immunodiffusion. Panel A: average AGP concentrations in
mice with different disease stages or treatment status. Group 1 normal mice;
group 2  mice treated with STI571 at a dose of 160 mg/kg every 8 hours for
11 days and sampled 3 days after treatment was discontinued; group 3  mice
bearing a tumor 8 days after tumor cell injection (average tumor weight 304
mg; 95% confidence interval [CI]  188–420); and group 4  mice bearing a
tumor 15 days after tumor cell injection (average tumor weight 1184 mg; 95%
CI  889–1479). Panel B: direct determination of AGP in normal and tumor-
bearing mice by isoelectrofocusing. Lanes 1 and 2 normal mice; lanes 3 and
4  mice bearing large (>1 g) tumors. The region of the AGP isoforms with
isoelectric points between pH 3.4 and pH 4.0 is indicated by the bracket.
1646 ARTICLES Journal of the National Cancer Institute, Vol. 92, No. 20, October 18, 2000
STI571 but did not modify the IC50 of STI571 in the absence of
AGP. Thus, a direct interaction between erythromycin and
STI571 was excluded. To determine whether erythromycin af-
fected the STI571-mediated inhibition of Bcr-Abl kinase activity
(Fig. 7, B), we cultured KU812 cells with STI571, AGP, and/or
erythromycin at 37 °C for 60 minutes; cells were then lysed, and
Bcr-Abl kinase activity in the lysates was measured. STI571
inhibited the autophosphorylation of Bcr-Abl, AGP decreased
the ability of STI571 to inhibit this activity, and erythromycin
restored it. Thus, results from two assays demonstrate that eryth-
romycin and STI571 compete for binding to AGP, and thus the
presence of erythromycin increases the amount of free STI571.
In Vivo Effects of Erythromycin Treatment and STI571
Pretreatment
To confirm that erythromycin could reverse the observed in
vivo resistance to STI571, we injected mice with KU812 cells
and started STI571 treatment 11 days later, when the tumor load
was approximately 400 mg. (At this stage, we expected few or
no cures from a standard STI571 treatment.) The treatment
schedule that we used was STI571 at a dose of 160 mg/kg given
orally every 8 hours, either alone or in combination with eryth-
romycin estolate (350 mg/kg every 8 hours) for 21 days. This
formulation produced peak concentrations of more than 20 M
erythromycin (11). The combined treatment produced a statisti-
cally significantly higher tumor reduction on day 6 and then
from day 16 onward (Fig. 8, A). Tumors regressed progressively
in mice receiving the combined treatment, whereas some tumors
started to regrow during the last days of treatment in the group
given STI571 alone.
The effect of erythromycin was even more apparent when the
cure rates in the two groups were compared (Fig. 8, B). Of the
15 mice receiving STI571 alone, the tumor initially disappeared
from five, but it reappeared in four of these animals between
days 25 and 40, so that only one of 13 animals was cured at day
180 (last day of follow-up) (two tumor-bearing animals in this
group were accidentally killed at some point during treatment).
In the group receiving the combined treatment of erythromycin
and STI571, 14 of 15 mice became tumor free and a tumor had
recurred in only one mouse by day 30 (three tumor-free animals
were accidentally killed during the treatment procedure). There-
fore, 10 of 12 animals were cured by the combined treatment at
day 180, a value that is statistically significantly different
(P<.001) from the value (one of 13 animals) obtained in the
group receiving STI571 only. Control groups receiving erythro-
mycin alone did not show any evidence of tumor regression
(data not shown).
The effects of STI571 pretreatment on tumor growth by in-
jected leukemic cells were also evaluated. Mice that had been
pretreated with STI571 for 11 days or had not been pretreated
received an injection of 50 × 106 KU812 cells and were treated
with STI571 after 1 day (160 mg/kg every 8 hours for 11 days),
a treatment regimen that is expected to cure all of the animals.
None of the 14 controls (nonpretreated mice) developed tumors,
whereas seven of the 14 pretreated mice had detectable tumors
(P  .006). These results indicate that the elevated levels of
AGP induced by a previous STI571 treatment can also produce
a statistically significant biologic effect.
Thus, these results support the hypothesis that the binding of
STI571 to AGP inhibits its therapeutic activity and provide a
partial experimental confirmation for the use of erythromycin or
similar compounds to bypass in vivo resistance mediated by
AGP.
DISCUSSION
STI571 is a new type of antineoplastic drug that is specifi-
cally tailored to an oncogenic protein causally linked to several
Fig. 7. 1 Acid glycoprotein (AGP) and erythromycin effects on the ability of
STI571 to inhibit KU812 cell proliferation and BCR/ABL autophosphorylation.
Panel A: KU812 cells were cultured with STI571 (  1 M), AGP (  1
mg/mL), or both STI571 (1 M) and AGP (1 mg/mL) () in the presence of
increasing concentrations of erythromycin (0–30 M). Cells were then pulse
labeled with [3H]thymidine and harvested. Data are the percent of untreated
control cells. All data are presented as means, with 95% confidence intervals
(CIs). CIs are displayed when they exceed 5% of the respective mean. Panel B:
Approximately 3 × 106 KU812 cells were incubated per well at 37 °C with an
eryrthromycin base (100 M), STI571 (3 M), and/or AGP (2 mg/mL), as
indicated. After 1 hour, cells were washed twice with ice-cold phosphate-
buffered saline and subsequently lysed in 500 L of 1× Laemmli’s buffer (8).
Cell lysates corresponding to 90 000 cells were analyzed by sodium dodecyl
sulfate–polyacrylamide electrophoresis on 7.5% gels. Total endogenous Bcr-Abl
(anti-Abl) and tyrosine-phosphorylated Bcr-Abl (anti-PTyr) were detected with
the mouse monoclonal antibody indicated. The results of one representative
experiment are presented. The experiment was performed two times with similar
results.
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human cancers. The antileukemic activity of STI571 is well
documented in vitro and in vivo (4–8). STI571 is not absolutely
specific; in fact, it inhibits the normal Abl protein and the re-
ceptor tyrosine kinases c-kit and platelet-derived growth factor-
. However, the toxic profile of STI571 seems benign, with few
normal cells being affected and very limited side effects ob-
served so far in treated patients (6,16).
Because STI571 is an inhibitor of Bcr-Abl, the development
of resistance is an important issue. Resistance can develop as a
result of various factors operating at the cellular level or the
organismal level. Drug resistance can develop, for example, be-
cause of mutation/amplification of the target gene (10,17,18),
induction of drug metabolism (19), or, paradoxically, increased
post-translational degradation of the target protein (20,21).
Recently, BCR-ABL gene amplification was observed in a
cell line (derived from a patient with CML) that had been se-
lected for resistance to STI571 (10). This cell line, however, was
selected in vitro, and this type of resistance has not yet been
observed in vivo. In this article, we report the induction and
characterization of resistance to STI571 in vivo. The mechanism
underlying this resistance was traced to the induction of AGP, a
plasma protein that binds STI571 tightly and inhibits its ability
to interact with Bcr-Abl kinase. Consistent with the fact that
resistance did not originate intracellularly in the tumor cell, in
vitro assays did not demonstrate any intrinsic resistance to
STI571, although differences in sensitivity to low STI571 con-
centrations (<0.3 M) cannot be ruled out. We showed that
physiologic concentrations of AGP could bind and block
STI571. In our animal model, AGP was clearly induced by the
injected tumor cells, and the levels of AGP were related to the
tumor load. Treatment with STI571 was also shown to increase
AGP plasma levels in mice, although to a lower extent. Eryth-
romycin reversed the effects of AGP in vitro. When adminis-
tered at doses able to produce in vivo concentrations of at least
Fig. 8. Co-administration of erythromycin and
STI571 to tumor-bearing mice. Animals bearing
a tumor 11 days after tumor cell injection were
randomly assigned to one of two groups. Fifteen
mice were treated with STI571 and erythromy-
cin (average tumor weight 385 mg; 95% con-
fidence interval [CI]  332–438), and 15 addi-
tional animals received STI571 only (mean
tumor weight  390 mg; 95% CI  276–504).
The treatment schedule that we used was STI571
at a dose of 160 mg/kg given orally every 8
hours, either alone or in combination with eryth-
romycin estolate (350 mg/kg every 8 hours) for
21 days. Control animals received erythromycin
in 5% methylcellulose (five mice) or in 5%
methylcellulose alone (six mice). Panel A:
Mean tumor weights measured during treatment
(days 0–21) from mice treated with STI571
alone or with erythromycin and STI571 are
shown. Error bars represent 95% CIs. Panel B:
Percent of tumor-bearing mice is shown as a
function of time after the start of treatment. Mice
were treated for 21 days with STI571 (160 mg/
kg) and erythromycin (350 mg/kg) administered
every 8 hours. Error bars represent 95% CIs.
Numbers in parentheses indicate the number of
animals at risk.
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20 M, erythromycin substantially increased the therapeutic ac-
tivity of STI571 in vivo. It is important to note that erythromycin
had no effect in vitro in the absence of AGP, which excludes the
possibility that AGP directly affected the sensitivity of KU812
cells to STI571. Although erythromycin can interfere with the
metabolism of several drugs, in our in vivo model, erythromycin
augmented the antitumor activity of STI571 only when levels of
AGP were also increased. In fact, when mice were given an
injection of COLIA/PDGFB transfectants, which are sensitive to
STI571 treatment (22) but do not induce increased AGP levels in
mice (Gambacorti C: unpublished results), the therapeutic ef-
fects of a combined treatment with erythromycin and STI571
and a treatment with STI571 alone (Greco MA: personal com-
munication) were similar.
The increased AGP levels associated with advanced tumors
provide an explanation for the limited efficacy of STI571 in our
model. The increased AGP level apparently induced by STI571
pretreatment substantially reduced the therapeutic activity of
STI571. These data strongly suggest that AGP, when present in
increased concentrations, bound most of the STI571 adminis-
tered, blocked its diffusion from the blood to tissues and cells,
and thus blocked access to its biologic targets. It is also worth
noting that another molecule, UCN-01, with some structural
similarity to STI571, was reported to bind strongly to AGP and
thus reduce its biologic availability (15).
Because an initial tumor reduction was noted even in animals
bearing large tumors, some sort of selection is probably taking
place in the relapsed tumor. This selection, however, is possible
by the exposure of leukemic cells to STI571 at marginally active
concentrations (because most of the STI571 is bound to AGP),
a condition that was, in fact, exploited for selecting resistance in
vitro (10).
AGP is an acute-phase protein that is synthesized in the liver
and has an average molecular weight of 40 000 (14). AGP binds
neutral and basic drugs in a one-to-one molar ratio. Increased
levels of AGP have been described in a variety of pathologic
conditions, such as chronic inflammation, myocardial infarction,
and advanced cancer (14). The data presented herein are derived
from an animal model, and their clinical relevance remains to be
demonstrated. However, it has been observed in an ongoing
clinical trial that the majority of CML patients in blast crisis and
patients with relapsed Philadelphia chromosome-positive acute
lymphoblastic leukemia show only temporary responses to
STI571, which are soon followed by the development of resis-
tance, while the therapeutic effects seem more durable in CML
patients treated in chronic phase (16,23).
Substantial differences exist, however, between mice and hu-
mans. Mice have very low baseline AGP levels (<100 mg/mL),
whereas humans have higher and wider baseline AGP levels
(400–800 mg/mL). Thus, under normal conditions, the fraction
of STI571 bound to AGP should be considerably higher in hu-
mans than in mice. For example, at STI571 concentrations found
in patients (1–10 M) and at murine AGP levels (<2.5 M), the
AGP-bound fraction of STI571 can be between 40% and 60%,
whereas at the same STI571 concentrations and normal human
AGP levels (10–20 M), the AGP-bound fraction of STI571 is
less than 10%. Thus, a mouse with normal AGP values retains a
substantial fraction of free STI571, but a leukemia patient, who
has higher levels of AGP, does not. Furthermore, exposure of
CML cells to marginally active STI571 concentrations could
facilitate the emergence of resistant leukemic cells, especially in
patients in blast crisis when additional genetic alterations induce
a higher degree of heterogeneity.
Therefore, the bioavailability of STI571 can be substantially
modified by the presence of AGP. The four to eight times higher
levels of AGP in humans than in mice could increase the half-
life of STI571, thus permitting STI571 to reach and maintain
more constant concentrations in humans than in mice. However,
the high AGP levels, including those associated with pathologic
conditions, could alter the tissue distribution of STI571 and the
cellular uptake of the drug, which would interfere with the ac-
cess of STI571 to its intracellular target protein, Bcr-Abl. The
concentration of free STI571 would be expected to increase
dramatically as dosages approached the stoichiometric equiva-
lence of STI571 to AGP. Drugs that compete with STI571 for
AGP binding could increase the concentration of free STI571
without the need to increase the total dose of STI571, a strategy
that we have used in our model. Extreme caution must be ex-
ercised, however, in transferring these data to clinical studies.
The results presented in this article were obtained in a murine
model that is characterized by baseline low AGP levels and that
used high doses of STI571 and erythromycin. Clearly, appropri-
ate pilot clinical studies will be needed to validate these results
in humans. Our data also indicate the need to assess free STI571
levels in addition to total plasma concentrations in designing
dosage and treatment schedules, to ensure an optimal tissue dis-
tribution of the drug, ideally combined with the concurrent
evaluation of surrogate markers of activity (e.g., the phosphor-
ylation status of Bcr-Abl) within the tumor.
In conclusion, we have identified the molecular nature of in
vivo resistance to STI571 in this model and have devised a
strategy to circumvent it. Our results indicate that in vivo resis-
tance to STI571 is caused by AGP, a plasma protein that is not
found in the target leukemic cells, but do not exclude the pos-
sibility that resistance to STI571 can develop by other mecha-
nisms (10). The decreased expression of BCL-XL in CML cells
treated with STI571 seems to be important in mediating the
apoptotic effect of STI571 (24). However, BCL-XL levels did
not change in BCR-ABL+ cells selected for resistance to STI571
(25). Further studies in vivo and in vitro will be needed to elu-
cidate the molecular mechanisms involved in determining sen-
sitivity or resistance to STI571 and to increase the therapeutic
potential of this promising and innovative drug.
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